Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch

References

• NewmanSPInhaler treatment options in COPDEur Respir Rev20051496102108
   Google Scholar
• MäkeläMJBackerVHedegaardMLarssonKAdherence to inhaled therapies, health outcomes and costs in patients with asthma and COPDRespir Med2013107101481149023643487
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseBethesda (MD)GOLD2014
   Google Scholar
• van NoordJABantjeTAElandMEKorduckiLCornelissenPJA randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotro-pium Study GroupThorax200055428929410722768
   PubMed Web of Science ®Google Scholar
• VinckenWvan NoordJAGreefhorstAPImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J200219220921611871363
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• DisseBSpeckGARomingerKLWitekTJJrHammerRTiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung diseaseLife Sci1999646–745746410069510
   PubMed Web of Science ®Google Scholar
• ZierenbergBOptimizing the in vitro performance of RespimatJ Aerosol Med199912Suppl 1S19S2410623337
   PubMedGoogle Scholar
• HodderRPriceDPatient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhalerInt J Chron Obstruct Pulmon Dis2009438139019888356
   PubMedGoogle Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
   PubMed Web of Science ®Google Scholar
• Van NoordJACornelissenPJAumannJLPlatzJMuellerAFogartyCThe efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patientsRespir Med20091031222919022642
   PubMed Web of Science ®Google Scholar
• LokeYKSinghSRisks associated with tiotropium in chronic obstructive airways disease: overview of the evidence to dateTher Adv Drug Saf20123312313125083231
   PubMedGoogle Scholar
• SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ2011342d321521672999
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• IchinoseMFujimotoTFukuchiYTiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patientsRespir Med2010104222823619969446
   PubMed Web of Science ®Google Scholar
• HohlfeldJMSharmaAvan NoordJAPharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary diseaseJ Clin Pharmacol201454440541424165906
   PubMed Web of Science ®Google Scholar
• ChorãoPPereiraAMFonsecaJAInhaler devices in asthma and COPD – an assessment of inhaler technique and patient preferencesRespir Med2014108796897524873873
   PubMed Web of Science ®Google Scholar
• BarronsRPegramABorriesAInhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary diseaseAm J Health Syst Pharm201168131221123221690428
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseBethesda (MD)GOLD2006
   Google Scholar
• TaffetGEDonohueJFAltmanPRConsiderations for managing chronic obstructive pulmonary disease in the elderlyClin Interv Aging20149233024376347
   PubMed Web of Science ®Google Scholar
• AmbrosinoNFoglioKBalzanoGPaggiaroPLLessiPKestenSTiotropium and exercise training in COPD patients: effects on dyspnea and exercise toleranceInt J Chron Obstruct Pulmon Dis20083477178019281092
   PubMedGoogle Scholar
• MaltaisFHamiltonAMarciniukDImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest200512831168117816162703
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• BatemanEDTashkinDSiafakasNA one-year trial of tiotropium Respimat plus usual therapy in COPD patientsRespir Med2010104101460147220620037
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• TroostersTCelliBLystigTTiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trialEur Respir J2010361657320185426
   PubMed Web of Science ®Google Scholar
• MoriceAHCelliBKestenSLystigTTashkinDDecramerMCOPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT)Respir Med2010104111659166720724131
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMKestenSLiuDMehraSTashkinDPMortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20091801094895519729663
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBRDecramerMLystigTLiuDKestenSEfficacy of tiotropium in COPD patients with FEV1 ≥60% participating in the UPLIFT trialCOPD20129328929622432932
   PubMedGoogle Scholar
• DahlRBackerVOllgaardBGerkenFKestenSAssessment of patient performance of the HandiHaler compared with the metered dose inhaler four weeks after instructionRespir Med200397101126113314561020
   PubMed Web of Science ®Google Scholar
• ChodoshSFlandersJSKestenSSerbyCWHochrainerDWitekTJJrEffective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severityJ Aerosol Med200114330931511693842
   PubMedGoogle Scholar
• AsakuraYNishimuraNMaezawaKTerajimaTKizuJChohna-bayashiNEffect of switching tiotropium HandiHaler to Respimat Soft Mist Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devicesJ Aerosol Med Pulm Drug Deliv2013261414522691112
   PubMed Web of Science ®Google Scholar
• PitcairnGReaderSPaviaDNewmanSDeposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhalerJ Aerosol Med200518326427216181001
   PubMedGoogle Scholar
• Rau-BergerHMitfesselHGlaabTTiotropium Respimat improves physical functioning in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2010536737321103403
   PubMedGoogle Scholar
• CaillaudDLe MerreCMartinatYAguilaniuBPaviaDA dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patientsInt J Chron Obstruct Pulmon Dis20072455956518268929
   PubMedGoogle Scholar
• FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology20049445846515612956
   PubMed Web of Science ®Google Scholar